Search results for: 'double detect bu'

The Chinese pharmaceutical market is expected to be the third-largest in the world in 2013. This research service analyzes various aspects of the Chinese pharmaceutical market between 2007 and 2016. Rising income, improving healthcare infrastructure, and insurance systems are some factors that drive this market. The study discusses in detail the ma...

This study provides data for the Russian in vitro diagnostics (IVD) market. Hematology, hemostasis (coagulation), urinalysis, microbiology, clinical chemistry, point of care testing, molecular diagnostics, immunochemistry, and others namely, tissue diagnostics and self-monitoring blood glucose, are the segments discussed in this market. Market reve...

This study provides data for the US in vitro diagnostics (IVD) market. Hematology, hemostasis (coagulation), urinalysis, microbiology, clinical chemistry, point of care testing, molecular diagnostics, tissue diagnostics, self-monitoring blood glucose, and immunochemistry are the segments in this market. Market revenues have been included in this de...

Despite global economic and industry challenges, in vitro diagnostics (IVD) markets are growing robustly at double the rate of the global pharmaceutical industry. The global IVD market size was $47.30 billion in 2013; it is expected to reach $62.63 billion in 2017, at a compound annual growth rate of 7.3%. Because of stagnating mature markets, comp...

The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house NGS technology use is expected to increase within the next 12 months. Data accuracy and operating costs are the top criteria for purchasing sequencing instruments. Disease-r...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

27 Aug 2020  |  Global  |  Market Research

Smart Labs as Key Drivers for the Digital Transformation of Diagnostic Laboratories, 2020

Robotic Automation, Internet of Things (IoT), and Artificial Intelligence (AI) Offering Growth Opportunities for Academic and Commercial Diagnostics Labs

Infographics

×

Key Issues Addressed

Diagnostic academic and commercial research labs suffer from cost pressures, given the ongoing Protecting Access to Medicare Act (PAMA) regulations and reproducibility issues, and are under productivity strain. The recent COVID-19 pandemic leading to increasing test volumes and renewed focus on research and development (R&D) to drive innovation wil...